JP7716110B2 - ピリミジン－４（３ｈ）－オンヘテロ環式化合物、その調製方法、およびその医薬的使用 - Google Patents
ピリミジン－４（３ｈ）－オンヘテロ環式化合物、その調製方法、およびその医薬的使用Info
- Publication number
- JP7716110B2 JP7716110B2 JP2022543700A JP2022543700A JP7716110B2 JP 7716110 B2 JP7716110 B2 JP 7716110B2 JP 2022543700 A JP2022543700 A JP 2022543700A JP 2022543700 A JP2022543700 A JP 2022543700A JP 7716110 B2 JP7716110 B2 JP 7716110B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- group
- ring
- alkyl
- reaction mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010056202.3 | 2020-01-19 | ||
| CN202010056202.3A CN113135910A (zh) | 2020-01-19 | 2020-01-19 | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 |
| PCT/CN2021/071375 WO2021143701A1 (zh) | 2020-01-19 | 2021-01-13 | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023511337A JP2023511337A (ja) | 2023-03-17 |
| JP2023511337A5 JP2023511337A5 (enExample) | 2024-01-22 |
| JP7716110B2 true JP7716110B2 (ja) | 2025-07-31 |
Family
ID=76808550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022543700A Active JP7716110B2 (ja) | 2020-01-19 | 2021-01-13 | ピリミジン－４（３ｈ）－オンヘテロ環式化合物、その調製方法、およびその医薬的使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230219946A1 (enExample) |
| EP (1) | EP4092024A4 (enExample) |
| JP (1) | JP7716110B2 (enExample) |
| KR (1) | KR102964789B1 (enExample) |
| CN (2) | CN113135910A (enExample) |
| AU (1) | AU2021208025B2 (enExample) |
| CA (1) | CA3168452A1 (enExample) |
| MX (1) | MX2022008881A (enExample) |
| WO (1) | WO2021143701A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| CN116848121A (zh) * | 2020-12-18 | 2023-10-03 | 建新公司 | 制备shp2抑制剂的方法 |
| WO2022133217A1 (en) * | 2020-12-18 | 2022-06-23 | Genzyme Corporation | Process for preparing shp2 inhibitors |
| PE20240088A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras |
| IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| TW202402761A (zh) * | 2022-03-28 | 2024-01-16 | 美商健臻公司 | 製備shp2抑制劑的方法 |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| CN121487951A (zh) | 2023-04-07 | 2026-02-06 | 锐新医药公司 | 大环ras抑制剂 |
| AU2024251341A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| EP4695261A1 (en) | 2023-04-14 | 2026-02-18 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN117720550A (zh) * | 2023-12-14 | 2024-03-19 | 深圳市华先医药科技有限公司 | (s)-3-甲基-4-氧代-2-氧杂-8-氮杂螺[4.5]癸烷-8-甲酸叔丁酯合成方法 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018517746A (ja) | 2015-06-19 | 2018-07-05 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための化合物および組成物 |
| WO2018130928A1 (en) | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
| JP2019521181A (ja) | 2016-06-07 | 2019-07-25 | ジャコバイオ ファーマスーティカルズ カンパニー リミテッドＪａｃｏｂｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． | Ｓｈｐ２阻害剤として有用な新規複素環式誘導体 |
| JP2019527728A (ja) | 2016-07-12 | 2019-10-03 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての２，５−二置換３−メチルピラジンおよび２，５，６−三置換３−メチルピラジン |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| EP3515916B1 (en) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| WO2021043077A1 (zh) * | 2019-09-06 | 2021-03-11 | 四川科伦博泰生物医药股份有限公司 | 一种取代吡嗪化合物、其制备方法和用途 |
-
2020
- 2020-01-19 CN CN202010056202.3A patent/CN113135910A/zh active Pending
-
2021
- 2021-01-13 AU AU2021208025A patent/AU2021208025B2/en active Active
- 2021-01-13 JP JP2022543700A patent/JP7716110B2/ja active Active
- 2021-01-13 CN CN202180009655.3A patent/CN114981268B/zh active Active
- 2021-01-13 WO PCT/CN2021/071375 patent/WO2021143701A1/zh not_active Ceased
- 2021-01-13 EP EP21741216.2A patent/EP4092024A4/en active Pending
- 2021-01-13 US US17/793,571 patent/US20230219946A1/en active Pending
- 2021-01-13 MX MX2022008881A patent/MX2022008881A/es unknown
- 2021-01-13 CA CA3168452A patent/CA3168452A1/en active Pending
- 2021-01-13 KR KR1020227028172A patent/KR102964789B1/ko active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018517746A (ja) | 2015-06-19 | 2018-07-05 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための化合物および組成物 |
| JP2019521181A (ja) | 2016-06-07 | 2019-07-25 | ジャコバイオ ファーマスーティカルズ カンパニー リミテッドＪａｃｏｂｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． | Ｓｈｐ２阻害剤として有用な新規複素環式誘導体 |
| JP2019527728A (ja) | 2016-07-12 | 2019-10-03 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての２，５−二置換３−メチルピラジンおよび２，５，６−三置換３−メチルピラジン |
| WO2018130928A1 (en) | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102964789B1 (ko) | 2026-05-15 |
| CN114981268B (zh) | 2025-01-28 |
| JP2023511337A (ja) | 2023-03-17 |
| CN114981268A (zh) | 2022-08-30 |
| EP4092024A1 (en) | 2022-11-23 |
| CN113135910A (zh) | 2021-07-20 |
| AU2021208025B2 (en) | 2026-06-04 |
| EP4092024A4 (en) | 2024-03-13 |
| KR20220130168A (ko) | 2022-09-26 |
| WO2021143701A1 (zh) | 2021-07-22 |
| AU2021208025A1 (en) | 2022-09-01 |
| US20230219946A1 (en) | 2023-07-13 |
| MX2022008881A (es) | 2022-08-11 |
| CA3168452A1 (en) | 2021-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023511337A (ja) | ピリミジン－４（３ｈ）－オンヘテロ環式化合物、その調製方法、およびその医薬的使用 | |
| CN111153901B (zh) | 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途 | |
| CN115667239B (zh) | 取代吡嗪类化合物，包含其的药物组合物及其用途 | |
| RU2742485C2 (ru) | Гетероциклическое соединение, используемое как ингибитор fgfr | |
| CN117800989A (zh) | 一类含环外双键、多取代甲基醚结构的化合物及其应用 | |
| RU2622104C2 (ru) | Макроциклические ингибиторы киназы lrrk2 | |
| WO2021218110A1 (zh) | 一类苯并噻唑基联芳基类化合物、制备方法和用途 | |
| WO2019037678A1 (zh) | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 | |
| CN117304183A (zh) | 五元并六元含氮化合物、其中间体、制备方法和应用 | |
| KR20190110588A (ko) | 알로스테릭 shp2 억제제로서의 피리딘 화합물 | |
| WO2020103897A1 (zh) | 杂环稠合嘧啶衍生物、其药物组合物及应用 | |
| KR20230035036A (ko) | 이중 키나제-브로모도메인 억제제 | |
| KR20220051226A (ko) | 아자헤테로아릴 화합물 및 이의 용도 | |
| KR20230058466A (ko) | 신규한 rho-연관 단백질 인산화효소 억제제의 제조 방법 및 제조 방법 중의 중간체 | |
| CN113387962A (zh) | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 | |
| WO2022272106A1 (en) | Cdk2 inhibitors and methods of using the same | |
| WO2021083383A1 (zh) | 一类含氮稠环类sting调节剂类化合物、制备方法和用途 | |
| CN112292374A (zh) | 一种新型磷酸肌醇3-激酶抑制剂及其制备方法和用途 | |
| WO2022017434A1 (zh) | 一类具有激酶抑制活性的化合物 | |
| CN114437116A (zh) | 杂环化合物及其制备方法、药物组合物和应用 | |
| CN120590414A (zh) | 一类含氮杂环类化合物、制备方法和用途 | |
| CN110734436A (zh) | 嘧啶或吡嗪并环化合物及其应用 | |
| CN112538084A (zh) | 新颖的kras g12c蛋白抑制剂及其制备方法和用途 | |
| CN111763217B (zh) | 一类噻吩并氮杂环类化合物、制备方法和用途 | |
| RU2839367C1 (ru) | Гетероциклическое соединение пиримидин-4(3h)-она, способ его получения и его фармацевтическое применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240112 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240112 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20241219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241224 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250319 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250401 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250625 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250701 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250711 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7716110 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |